Erasca stock tumbles 5% on cancer drug trial data
Investing.com Gold reports: Erasca stock tumbles 5% on cancer drug trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Erasca stock tumbles 5% on cancer drug trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.